Interactome develops multi-targeted biologics, called Secretomes, containing proteins and factors that promote cellular regeneration and modulate inflammation. Their platform aims to address underserved conditions in dermatology, oncology, and neurology by facilitating cell recovery and turnover.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for many dermatological, oncological, and neurological conditions often fail to fully address the underlying cellular damage and inflammatory responses, leading to incomplete recovery and persistent symptoms. Effective therapies are needed to promote cellular regeneration and modulate inflammation to achieve better patient outcomes.
Solution
Interactome Biotherapeutics is developing a novel biologic platform based on multi-targeted Secretomes, which contain a complex mixture of biologically active proteins and factors. These Secretomes are designed to promote cellular regeneration, modulate inflammation, and facilitate cell recovery and turnover. The platform leverages the natural communication mechanisms of cells, particularly progenitor cells, pericytes, stem cells, and exosomes, to develop therapies that can precisely target disease mechanisms and promote tissue regeneration. This approach aims to address the root causes of disease by tapping into the body's innate healing mechanisms, offering potential treatments for underserved conditions in dermatology, oncology, and neurology.
Target Audience
The primary target audience includes patients suffering from underserved conditions in dermatology, oncology, and neurology, as well as pharmaceutical companies seeking innovative drug delivery platforms and therapeutic candidates.
Features
- Multi-targeted Secretomes containing hundreds of biologically active proteins and factors
- Focus on cellular regeneration, modulation of inflammation, and cell recovery
- Utilizes exosomes as delivery vehicles for targeted therapies
- Engineered Small Extracellular Vesicles (sEV) as advanced delivery platforms for therapeutic molecules
- Engineered binding domain on sEVs to load nucleic acids, proteins, and small molecules without host cell modification
- Specialized transmembrane protein that increases EV cargo capacity and enables targeted delivery
- Native Nano Platform leveraging exosomes for immune silent drug delivery